What is the recommended post‑exposure prophylaxis for a healthy infant exposed to shingles (herpes‑zoster), including dosing and timing?

Post-Exposure Prophylaxis for Healthy Infants Exposed to Shingles

Healthy infants exposed to shingles (herpes zoster) generally do not require post-exposure prophylaxis unless they lack evidence of immunity to varicella and meet specific high-risk criteria. 1

Understanding Transmission Risk from Shingles

The risk of varicella-zoster virus (VZV) transmission from herpes zoster is approximately 20% of the risk from chickenpox, making it significantly less contagious. 1, 2 Transmission requires direct contact with fluid from active vesicles or, rarely in healthcare settings, airborne exposure to uncrusted lesions. 2 A person with shingles cannot transmit shingles itself—they can only transmit VZV, which causes chickenpox in susceptible individuals. 2

When VariZIG Is NOT Indicated

For healthy term infants with normal immune function who are exposed to shingles, VariZIG prophylaxis is not routinely recommended. 1 The CDC and ACIP guidelines reserve VariZIG for specific high-risk populations who lack evidence of immunity and for whom varicella vaccine is contraindicated. 1

High-Risk Infants Who DO Require VariZIG

VariZIG is indicated for the following infant populations exposed to varicella-zoster virus:

Neonates Born to Mothers with Peripartum Varicella

• Administer VariZIG immediately to newborns whose mothers develop varicella from 5 days before to 2 days after delivery, regardless of whether the mother received VariZIG. 1, 3 This represents the highest-risk scenario, with historical mortality rates of 31% without intervention. 1, 3
• Dosing: 125 units per 10 kg body weight (maximum 625 units) intramuscularly. 3, 4
• Timing: Administer as soon as possible after birth, ideally within 96 hours of exposure, but CDC recommends administration up to 10 days post-exposure. 1, 3

Premature Infants with Postnatal Exposure

• Very premature infants (<28 weeks gestation or <1,000g) should receive VariZIG regardless of maternal immunity status when exposed to varicella or herpes zoster during their hospitalization. 3
• Moderately premature infants (≥28 weeks gestation) should receive VariZIG only if the mother lacks evidence of immunity. 3
• The CDC has extended eligibility for premature infants from exposures during the neonatal period to exposures occurring during the entire period they require hospital care for prematurity. 1

Immunocompromised Infants

• Any infant with altered cell-mediated immunity who lacks evidence of varicella immunity should receive VariZIG after exposure to either varicella or herpes zoster. 1

Alternative: Oral Acyclovir Prophylaxis

If VariZIG is unavailable or for infants who do not meet high-risk criteria but have significant exposure concerns, oral acyclovir prophylaxis may be considered. 4, 5

• Studies demonstrate that oral acyclovir post-exposure prophylaxis is safe and effective, with secondary infection rates of only 1.3% in immunocompetent contacts compared to 18% without prophylaxis. 5
• Dosing for prophylaxis is typically 40-80 mg/kg/day divided into 3-4 doses, initiated within 7-10 days of exposure and continued for 7 days. 5, 6

If Varicella Develops Despite Prophylaxis

If varicella develops in a high-risk infant despite VariZIG prophylaxis, initiate intravenous acyclovir immediately. 3, 6

• Neonatal dosing: 10 mg/kg IV infused over 1 hour, every 8 hours for 10 days. 3
• Treatment is most effective when started within 24 hours of rash onset. 3
• Early commencement of acyclovir is recommended for newborns during the first 2 weeks of life with varicella. 6

Clinical Algorithm for Healthy Infants Exposed to Shingles

1. Assess infant risk category:

   • Term, healthy infant with normal immune function → No prophylaxis needed 1
   • Neonate born to mother with varicella 5 days before to 2 days after delivery → VariZIG immediately 1, 3
   • Very premature infant (<28 weeks or <1,000g) → VariZIG regardless of maternal immunity 3
   • Moderately premature infant (≥28 weeks) → VariZIG only if mother lacks immunity 3
   • Immunocompromised infant → VariZIG if no evidence of immunity 1

2. Verify maternal immunity status (if relevant) through documented history of varicella, vaccination records, or IgG serology. 7

3. Administer VariZIG within 96 hours ideally, but up to 10 days post-exposure for eligible infants. 1, 8 Recent evidence shows similar efficacy when administered within 10 days versus within 96 hours. 8

4. Monitor for varicella development for 42 days after exposure. 8 Even with VariZIG, approximately 11.5% of infants may still develop varicella, though severity is reduced. 8

Critical Pitfalls to Avoid

• Do not administer VariZIG to healthy term infants with normal immune function—this represents unnecessary intervention and resource utilization. 1
• Do not assume VariZIG prevents infection—it reduces severity and mortality but approximately 60% may still develop varicella. 3
• Do not delay acyclovir if varicella develops—efficacy decreases significantly after 24 hours of rash onset. 3
• Do not withhold VariZIG from neonates born 5 days before to 2 days after maternal rash onset, even if the mother received VariZIG. 3
• Do not confuse exposure to shingles with exposure to chickenpox—the transmission risk from shingles is only 20% that of chickenpox. 1, 2